Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

Research and Innovation Action · Running

VOLABIOS Validation and Comparitive Multi-Omics Benchmarking of Fluid-Derived Volatilomics Biomarkers for the Prevention and Early detection of Schizophrenia

Coordinator
Technion - Israel Institute of Technology, Israel
Runs
1 January 2025 to 30 June 2029
Status
Running
EU funding
€8.0m
Total cost
—
Partners
22 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101156162

What the project is doing

In the project's own words, from its summary on CORDIS.

Schizophrenia (SZ) impacts around 1% of the global population, posing diagnostic challenges that lead to a misdiagnosis rate of 23-40%. The need for reliable biomarkers is crucial to improve early detection and treatment outcomes. VOLABIOS aims to revolutionize SZ management by harnessing innovative real-time and portable spectrograph technology to validate volatile organic compounds (VOCs) as non-invasive and cost-effective biomarkers detectable during the early stages of the disease.

This entails extensive data analysis, prospective clinical studies involving 3,692 subjects across six centres, and a blind validation study with 1,000 subjects, focusing on longitudinal monitoring of at-risk individuals to identify early SZ transition. To further substantiate the efficacy of VOCs and gain profound insights, VOLABIOS will integrate VOC analysis with genomics, proteomics, and transcriptomics. This integration will be supported by a biobank comprising approximately 4,000 samples and a dataset consisting of 9 million records.

By considering external and personal risk factors as well as biological responses, VOLABIOS aims to unravel intricate correlations that contribute to SZ development. This comprehensive approach will enhance prediction accuracy, facilitate early detection, and improve management strategies. Furthermore, VOLABIOS plans to explore the real-time effects of validated VOCs through controlled in-vivo experiments using animal models, providing valuable information about associated cellular and molecular pathways.

VOLABIOS's endeavours to validate and establish EU-wide SZ diagnosis protocols are set to significantly enhance patient care and healthcare efficiency, marking a substantial step forward in addressing the complexities surrounding SZ.

Who is involved

OrganisationCityCountryRole
Technion - Israel Institute of TechnologyHaifaIsraelCoordinator
Zentrum Fur Soziale Innovation GmbHWienAustriaParticipant
Ainigma TechnologiesLeuvenBelgiumParticipant
TimelexBruxelles / BrusselBelgiumParticipant
Betthera SroHradec KraloveCzechiaParticipant
Gesellschaft Zur Forderung Empirisch Begrundeter TherapieansatzeAachenGermanyParticipant
Heinrich-Heine-Universitaet DuesseldorfDusseldorfGermanyParticipant
Universitaetsklinikum AachenAachenGermanyParticipant
Cubic Snail O.e.ThessalonikiGreeceParticipant
Ethniko Kentro Erevnas Kai Technologikis AnaptyxisThermi ThessalonikiGreeceParticipant
Exus Software Monoprosopi Etairia Periorismenis EvthinisAthinaGreeceParticipant
Ypourgeio YgeiasAthinaGreeceParticipant
Fundacion Para La Gestion De La Investigacion En Salud De SevillaSevillaSpainThird party
Servicio Andaluz De SaludSevillaSpainParticipant
Universidad De La RiojaLogronoSpainParticipant
FiralisHuningueFranceParticipant
Firalis Molecular Precision SAHuningueFranceThird party
Smart Nano Sense LtdHaifaIsraelParticipant
Technion Research and Development Foundation LtdHaifaIsraelThird party
Lietuvos Sveikatos Mokslu UniversitetasKaunasLithuaniaParticipant
Universidade De CoimbraCoimbraPortugalParticipant
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI